EDNRA and pulmonary arterial hypertension: Our in vitro results suggest that Orai1 inhibition is complementary to endothelin-1 receptor inhibitor (ambrisentan) or PDE5 inhibition (sildenafil) used in standard PAH therapy (Figure 7A).